Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKUS Akouos (AKUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Akouos Stock (NASDAQ:AKUS) 30 days 90 days 365 days Advanced Chart Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Akouos alerts:Sign Up Key Stats Today's Range$13.29▼$13.2950-Day Range$13.29▼$13.2952-Week Range$2.32▼$13.60Volume440 shsAverage Volume344,411 shsMarket Capitalization$490.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Receive AKUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter. Email Address AKUS Stock News HeadlinesNOVARTIS AG's Net WorthMay 3, 2024 | benzinga.comJoshua Makower's Net WorthApril 5, 2024 | benzinga.comHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…November 17, 2024 | WealthPress (Ad)William W. Backus HospitalMay 17, 2023 | health.usnews.comRectify Pharmaceuticals Appoints Sachiyo Minegishi as Chief Operating OfficerMay 16, 2023 | finance.yahoo.comLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesDecember 1, 2022 | finance.yahoo.comAkouos Reports Third Quarter 2022 Financial Results and Provides Business HighlightsNovember 14, 2022 | finance.yahoo.comAkouos stock soars 87% as Lilly nabs hearing loss gene therapy developer - Seeking AlphaOctober 19, 2022 | seekingalpha.comSee More Headlines AKUS Stock Analysis - Frequently Asked Questions How were Akouos' earnings last quarter? Akouos, Inc. (NASDAQ:AKUS) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.04. When did Akouos IPO? Akouos (AKUS) raised $124 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Akouos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akouos investors own include Advanced Micro Devices (AMD), Atreca (BCEL), Editas Medicine (EDIT), Homology Medicines (FIXX), Avidity Biosciences (RNA), Alector (ALEC) and Gossamer Bio (GOSS). Company Calendar Last Earnings11/12/2021Today11/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKUS CUSIPN/A CIK1722271 Webwww.akouos.com Phone857-410-1818FaxN/AEmployees103Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.09% Return on Assets-36.86% Debt Debt-to-Equity RatioN/A Current Ratio17.30 Quick Ratio17.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.71Miscellaneous Outstanding Shares36,936,000Free Float35,163,000Market Cap$490.88 million OptionableNot Optionable Beta-0.55 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:AKUS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akouos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akouos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
